Drug intelligence / Profile preview

CelestaPro Numbing Cream

Development stage
Unknown
Lead developer
CelestaPro
Modality
Small Molecules
Administration
Topical
01

Overview

CelestaPro Numbing Cream is a topical local anesthetic formulation distributed by CelestaPro, a Korean aesthetic products platform. It is designed to provide temporary surface anesthesia prior to minimally invasive aesthetic and dermatological procedures, such as dermal filler injections, botulinum toxin applications, microneedling, and laser therapy. The product typically contains lidocaine as its primary active ingredient, which functions by blocking voltage-gated sodium channels in sensory neurons. This action prevents the initiation and conduction of nerve impulses, effectively inhibiting the transmission of pain signals from the skin surface to the central nervous system. It is marketed for professional use in clinical and aesthetic settings to enhance patient comfort during procedural interventions.

Brand names
CelestaPro Numbing Cream
Other names
CelestaPro Topical Anesthetic
02

Targets

SCN10A (Sodium channel protein type X alpha subunit)SCN9A (Sodium channel protein type 9 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on CelestaPro Numbing Cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CelestaPro Numbing Cream.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call